cbdMD, Inc.

YCBD

US12482W3097

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.9 ^USD	0.00%		-9.93%	-13.46%

Apr. 02	CbdMD, Inc. Appoints Brad Whitford as Chief Accounting Officer, Treasurer and Secretary	CI
Mar. 29	Transcript : CbdMD, Inc. - Shareholder/Analyst Call

CbdMD, Inc. Announces Resignation of Martin Sumichrast as CEO

June 13, 2022 at 04:07 pm EDT

cbdMD, Inc. announced that Martin Sumichrast has resigned as CEO effective immediately. Board member Scott Coffman, former co-CEO and the operating company founder, will consult with the Board of Directors in leading the company until a new CEO is named.

Latest news about cbdMD, Inc.

CbdMD, Inc. Appoints Brad Whitford as Chief Accounting Officer, Treasurer and Secretary	Apr. 02	CI
Transcript : CbdMD, Inc. - Shareholder/Analyst Call	Mar. 29
Earnings Flash (YCBD) CBDMD Posts Q1 Revenue $5.4M	Feb. 13	MT
CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 13	CI
CbdMD, Inc. announced that it expects to receive $1.25 million in funding	Jan. 29	CI
Earnings Flash (YCBD) CBDMD Posts Q4 Revenue $24.2M	Dec. 22	MT
CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 22	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	23-10-05	MT
Transcript : CbdMD, Inc. - Shareholder/Analyst Call	23-09-22
CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (YCBD) CBDMD Posts Q3 Revenue $6.1M	23-08-10	MT
Transcript : CbdMD, Inc., Q3 2023 Earnings Call, Aug 10, 2023	23-08-10
Certain Restricted Stock Units of cbdMD, Inc. are subject to a Lock-Up Agreement Ending on 30-JUL-2023.	23-07-29	CI
Certain Warrants of cbdMD, Inc. are subject to a Lock-Up Agreement Ending on 30-JUL-2023.	23-07-29	CI
Certain Options of cbdMD, Inc. are subject to a Lock-Up Agreement Ending on 30-JUL-2023.	23-07-29	CI
Certain Common Stock of cbdMD, Inc. are subject to a Lock-Up Agreement Ending on 30-JUL-2023.	23-07-29	CI
Certain Series A Convertible Preferred Stock of cbdMD, Inc. are subject to a Lock-Up Agreement Ending on 30-JUL-2023.	23-07-29	CI
CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Earnings Flash (YCBD) CBDMD Posts Q2 Revenue $6.2M	23-05-15	MT
Transcript : CbdMD, Inc., Q2 2023 Earnings Call, May 15, 2023	23-05-15
Top Midday Decliners	23-05-01	MT
US Stocks Set to Open Relatively Flat Ahead of Manufacturing, Construction Spending Data	23-05-01	MT
Top Premarket Decliners	23-05-01	MT

Chart cbdMD, Inc.

Duration

Period

More charts

Company Profile

cbdMD, Inc. produces and distributes cannabidiol (CBD) products. The Company owns and operates CBD brands cbdMD, Paw CBD and cbdMD Botanicals. Its cbdMD brand of products includes a range of premium every day and functional CBD products, including tinctures; gummies; topicals; capsules; drink mixes; and sleep, focus and calming aids.Its Paw CBD brand of products includes a line of veterinarian-formulated products including tinctures, chews, topicals products in varying strengths and formulas. Its cbdMD Botanicals brand of beauty and skincare products features facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care stock-keeping units (SKU). cbdMD, Paw CBD and cbdMD Botanicals products are distributed through its e-commerce websites, third party ecommerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers. Its products are sold through www.cbdmd.com, www.pawcbd.com, and cbdmdbotanicals.com Websites.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for cbdMD, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.9 USD

Average target price

2 USD

Spread / Average Target

+122.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CBDMD, INC.	-13.46%	2.74M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals

cbdMD, Inc.

Equities

YCBD

US12482W3097

Pharmaceuticals

CbdMD, Inc. Announces Resignation of Martin Sumichrast as CEO

EPS Revisions